{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Choice+Behavior&page=2", "query": { "condition": "Choice Behavior", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Choice+Behavior&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T09:43:56.894Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06346392", "title": "AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "AZD0901", "type": "DRUG" }, { "name": "Ramucirumab+ paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "TAS-102", "type": "DRUG" }, { "name": "Apatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 572, "start_date": "2024-03-04", "completion_date": "2026-09-14", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-05-22T09:43:56.894Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06346392" }, { "nct_id": "NCT03734029", "title": "Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan (DS-8201a)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 557, "start_date": "2018-12-27", "completion_date": "2026-08-01", "has_results": true, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-05-22T09:43:56.894Z", "location_count": 38, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03734029" }, { "nct_id": "NCT06463665", "title": "Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-squamous Non-small-cell Lung Cancer", "Advanced Squamous Non-Small Cell Lung Carcinoma", "Metastatic Non-squamous Non Small Cell Lung Cancer", "Metastatic Squamous Non-Small Cell Lung Carcinoma", "Non-small Cell Lung Cancer", "Non-small Cell Lung Cancer Stage III", "Non-small Cell Lung Cancer Stage IV", "Non-small Cell Lung Cancer Recurrent" ], "interventions": [ { "name": "Olvimulogene nanivacirepvec", "type": "BIOLOGICAL" }, { "name": "Platinum chemotherapy: carboplatin or cisplatin", "type": "DRUG" }, { "name": "Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC", "type": "DRUG" }, { "name": "Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genelux Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2024-09-26", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2025-09-26", "last_synced_at": "2026-05-22T09:43:56.894Z", "location_count": 16, "location_summary": "Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 12 more", "locations": [ { "city": "Bullhead City", "state": "Arizona" }, { "city": "Clermont", "state": "Florida" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06463665" }, { "nct_id": "NCT05563506", "title": "The Healthy Kids+ Initiative: Promoting Active Living Through Healthy Choices", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Health Behavior" ], "interventions": [ { "name": "Healthy Kids +", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "New Mexico State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "8 Years to 11 Years" }, "enrollment_count": 60, "start_date": "2023-01-23", "completion_date": "2025-07-30", "has_results": false, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-05-22T09:43:56.894Z", "location_count": 2, "location_summary": "Las Cruces, New Mexico", "locations": [ { "city": "Las Cruces", "state": "New Mexico" }, { "city": "Las Cruces", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT05563506" }, { "nct_id": "NCT02375815", "title": "Statin Choice Decision Aid Implementation First Phase", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiovascular Factor Risk" ], "interventions": [ { "name": "Statin Choice Implementation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 313, "start_date": "2015-01", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2017-03-24", "last_synced_at": "2026-05-22T09:43:56.894Z", "location_count": 4, "location_summary": "Coeur d'Alene, Idaho • Rochester, Minnesota • Saint Joseph, Missouri + 1 more", "locations": [ { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Saint Joseph", "state": "Missouri" }, { "city": "Grand Forks", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02375815" }, { "nct_id": "NCT04740008", "title": "Impact of Low Nicotine Cigarette Messaging on Perceptions and Cigarette Choices", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Smoking", "Cigarette" ], "interventions": [ { "name": "Low Nicotine Content Cigarettes", "type": "DRUG" }, { "name": "Control message", "type": "OTHER" }, { "name": "Test message", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 64, "start_date": "2021-04-20", "completion_date": "2022-08-24", "has_results": false, "last_update_posted_date": "2024-02-26", "last_synced_at": "2026-05-22T09:43:56.894Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04740008" }, { "nct_id": "NCT06673095", "title": "Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clinical Stage IA Cutaneous Melanoma AJCC v8", "Clinical Stage IB Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Excision", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2024-12-11", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-05-22T09:43:56.894Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06673095" }, { "nct_id": "NCT04896411", "title": "Choice of Diction's Effect", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Communication", "Advance Directives", "Decision Making", "Cardiopulmonary Resuscitation" ], "interventions": [ { "name": "Alternative phrasing for no code", "type": "OTHER" }, { "name": "Standard of care for no code", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 100, "start_date": "2021-08-09", "completion_date": "2023-02-08", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-05-22T09:43:56.894Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04896411" }, { "nct_id": "NCT01905592", "title": "A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Breast", "Carcinoma of Breast", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Ovarian Neoplasms" ], "interventions": [ { "name": "niraparib", "type": "DRUG" }, { "name": "Physician's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2014-02-25", "completion_date": "2021-10-26", "has_results": true, "last_update_posted_date": "2022-11-15", "last_synced_at": "2026-05-22T09:43:56.894Z", "location_count": 25, "location_summary": "Tucson, Arizona • Los Angeles, California • Fort Myers, Florida + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01905592" }, { "nct_id": "NCT07060807", "title": "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Liposomal doxorubicin", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2025-07-21", "completion_date": "2033-07-14", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-05-22T09:43:56.894Z", "location_count": 33, "location_summary": "Daphne, Alabama • Tucson, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07060807" } ] }